Last updated: August 17, 2026

Examiner: ANGELL, JON E

Tech Center 1600 • Art Units: 1635 1637 1642 1674

This examiner grants 71% of resolved cases

Performance Statistics

70.9%

Allow Rate

+10.9% vs TC avg

859

Total Applications

+21.1%

Interview Lift

1194

Avg Prosecution Days

Based on 821 resolved cases, 2023–2026

6.8%

§101 Eligibility

23.2%

§102 Novelty

27.5%

§103 Obviousness

26.6%

§112 Clarity

App #	Title	Status	Assignee
18192108	DOUBLE-STRANDED RNA THAT INHIBITS PRODUCTION OF HEPATITIS B VIRUS PROTEIN AND PHARMACEUTICAL COMPOSITION	Non-Final OA	FUJIFILM Corporation
17797810	RNA-LOADED NANOPARTICLES AND USE THEREOF FOR THE TREATMENT OF CANCER	Final Rejection	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
17637427	TARGETING SLC38A2 IN PANCREATIC CANCER	Non-Final OA	New York University
18365991	Weight Loss Regimen	Non-Final OA	Board of Regents, The University of Texas System

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.